利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

448 条记录 (耗时 0.024 秒)

    TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS
    71.
    发明申请
    TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS 审中-公开
    用热冲击/应激蛋白治疗或预防神经性和感染性疾病

    公开(公告)号：WO1997010001A1

    公开(公告)日：1997-03-20

    申请号：PCT/US1996014557

    申请日：1996-09-11

    申请人： FORDHAM UNIVERSITY

    发明人： FORDHAM UNIVERSITY ,  SRIVASTAVA, Pramod, K.

    IPC分类号： A61K39/385

    CPC分类号： A61K39/0011 ,  A61K2039/5152 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/6043 ,  A61K2039/622 ,  G01N33/56977 ,  G01N33/574 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/466 ,  Y02A50/478 ,  Y10S435/81

    摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 100-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.

    摘要翻译： 本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。 本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。 本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即，hsps在体内不复合的肽或其抗原性/免疫原性片段及其衍生物） 复合物对于个体是自体的，复合物的有效量对于包含hsp70，hsp90为50-1000微克，gp96为10-600微克的复合物为100-600微克，本发明还提供 一种用于测量个体，优选人体内肿瘤排斥反应的方法，包括测量个体对肿瘤特异性的MHC I类限制性CD8 +细胞毒性T淋巴细胞的产生。还提供了纯化hsp70-肽复合物的方法。

    APIDAECIN-TYPE PEPTIDE ANTIBIOTICS WITH IMPROVED ACTIVITIES AND/OR DIFFERENT ANTIBACTERIAL SPECTRUM
    72.
    发明申请
    APIDAECIN-TYPE PEPTIDE ANTIBIOTICS WITH IMPROVED ACTIVITIES AND/OR DIFFERENT ANTIBACTERIAL SPECTRUM 审中-公开
    具有改善活性和/或不同抗菌谱的APIDAECIN型抗生素

    公开(公告)号：WO1995023513A1

    公开(公告)日：1995-09-08

    申请号：PCT/US1995002626

    申请日：1995-03-02

    申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  TEMPST, Paul ,  CASTEELS, Peter

    发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

    IPC分类号： A01N63/02

    CPC分类号： A01N63/00 ,  A01N37/46 ,  A61K38/00 ,  C07K14/435 ,  C07K16/18 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/483

    摘要： This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a third sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the third sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a third sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the third sequence is N-terminal to the first sequence; and a fourth sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the fourth sequence is N-terminal to the second sequence.

    摘要翻译： 本发明提供了具有抗细菌活性的纯化多肽，其包含第一序列Pro-Arg-Pro-Pro-His-Pro-Arg-X1，其中X 1是Ile或Leu; 和第三序列X2-Pro-X3-X4-X5-Pro，其中X2是Arg或Lys，X3是Thr，Gln或Arg，X4是Tyr，Gln或Pro，X5是Val或Ala，第三个序列是 第一个序列的N端。 本发明还提供具有抗菌活性的纯化多肽，其包含：第一序列，至少七个氨基酸残基与Pro-Arg-Pro-Pro-His-Pro-Arg-X1相同，其中X1为Ile或Leu; 第三序列X2-Pro-X3-X4-X5-Pro，其中X2为Arg或Lys，X3为Thr，Gln或Arg，X4为Tyr，Gln或Pro，X5为Val或Ala，第三序列为N - 第一个序列的末端 和包含至少五个氨基酸残基的第四序列，至少三分之一的残基是Pro，第四个序列是第二个序列的N末端。

    BACTERIAL VACCINE AGAINST LEGIONELLA PNEUMOPHILA AND OTHER VIRULENT PATHOGENS
    74.
    发明申请
    BACTERIAL VACCINE AGAINST LEGIONELLA PNEUMOPHILA AND OTHER VIRULENT PATHOGENS 审中-公开
    细菌疫苗对抗风湿性膀胱炎及其他病毒性病原体

    公开(公告)号：WO1990001945A1

    公开(公告)日：1990-03-08

    申请号：PCT/US1989003488

    申请日：1989-08-15

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  HORWITZ, Marcus, A.

    IPC分类号： A61K39/02

    CPC分类号： A61K39/0208 ,  C12N15/01 ,  Y02A50/478

    摘要： A method for producing stable avirulent mutant strains of Legionella pneumophila for use as vaccines and vehicles for immunization with antigens to other pathogens, and the bacteria so produced are disclosed and claimed. The method involves passing wild-type bacteria on suboptimal artificial media and selecting individual mutant clones which are subsequently passed on suboptimal artificial media. The bacteria so produced are useful as vaccines and as intracellular target vehicles for transporting antigens from a variety of pathogens and may be administered through the aerosol route as well as conventional means of administration.

    摘要翻译： 用于生产用于疫苗的稳定的无毒力突变菌株的方法，用于将抗原与其他病原体免疫的疫苗以及如此生产的细菌的方法。 该方法包括将野生型细菌通入次优人造培养基上，并选择随后在次最佳人造培养基上通过的单个突变体克隆。 如此产生的细菌可用作疫苗和用作从各种病原体输送抗原的细胞内靶载体，并且可以通过气溶胶路线以及常规的施用方式施用。

    IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY
    77.
    发明申请
    IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY 审中-公开
    免疫抑制剂及其治疗用途

    公开(公告)号：WO2016177898A1

    公开(公告)日：2016-11-10

    申请号：PCT/EP2016/060231

    申请日：2016-05-06

    申请人： NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU)

    发明人： OTTERLEI, Marit

    IPC分类号： A61K38/17 ,  C07K14/435 ,  A61P37/00

    CPC分类号： A61K38/1709 ,  C07K14/52 ,  Y02A50/385 ,  Y02A50/411 ,  Y02A50/423 ,  Y02A50/478 ,  Y02A50/481

    摘要： The present invention provides an agent, or composition containing an agent, for use in treating or preventing hypercytokinemia in a subject resulting from cytokine release from non-proliferating immune cells in blood, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X 1 X 2 X 3 X 4 X 5 X 6 (SEQ ID NO: 1 ) and wherein: X 1 is a basic amino acid; X 2 is an aromatic amino acid; X 3 is an aromatic amino acid or a hydrophobic amino acid that has an R group comprising at least three carbon atoms; X 4 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X 5 is any amino acid other than an acidic amino acid or an aromatic amino acid; and X 6 is any amino acid other than an acidic amino acid or an aromatic amino acid, preferably a basic amino acid or Proline (P), wherein when X 3 is not an aromatic amino acid, X 5 is not lysine (K) and X 6 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and composition of the invention may be used as single agents. In other aspects of the invention the agents and composition may be used in conjunction with one or more additional active agents, such as kinase inhibitors.

    摘要翻译： 本发明提供了一种用于治疗或预防由血液中的非增殖性免疫细胞释放细胞因子而产生的高细胞因子血症的试剂或组合物，其中所述试剂包含：（i）包含PCNA的寡肽化合物 促进所述化合物的细胞摄取的相互作用基序和结构域，其中所述PCNA相互作用基序是X1X2X3X4X5X6（SEQ ID NO：1），其中：X1是碱性氨基酸; X2是芳香族氨基酸; X3是具有至少三个碳原子的R基团的芳族氨基酸或疏水性氨基酸; X4是除芳香族氨基酸，甘氨酸（G）和脯氨酸（P）之外的不带电荷的氨基酸; X5是酸性氨基酸或芳香族氨基酸以外的氨基酸; X6是酸性氨基酸或芳香族氨基酸，优选碱性氨基酸或脯氨酸（P）以外的氨基酸，其中，当X3不是芳香族氨基酸时，X5不是赖氨酸（K），X6是 碱性氨基酸或脯氨酸（P）; 或（ii）包含编码（i）的寡肽化合物的序列的核酸分子。 在某些方面，本发明的试剂和组合物可以用作单一试剂。 在本发明的其它方面，试剂和组合物可以与一种或多种另外的活性剂如激酶抑制剂结合使用。

    COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS
    78.
    发明申请
    COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS 审中-公开
    联合治疗有效的微生物，包括耐药微生物

    公开(公告)号：WO2016081592A1

    公开(公告)日：2016-05-26

    申请号：PCT/US2015/061324

    申请日：2015-11-18

    申请人： FLEURIR ABX LLC

    发明人： PACE, John, Lee ,  WILES, Marc, Edwin ,  ADAMS, Stacy, Michelle ,  HUSSEY, Elizabeth

    IPC分类号： A61K31/665 ,  A61K31/18 ,  A61K31/44 ,  A61K31/63 ,  A61K45/00 ,  A61P11/00 ,  A61P11/08 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P31/00 ,  A61P31/04 ,  A61P33/00

    CPC分类号： A61K31/665 ,  A61K31/505 ,  A61K31/635 ,  A61K45/06 ,  Y02A50/473 ,  Y02A50/478 ,  A61K2300/00

    摘要： Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria. These novel compositions are also effective against microorganisms or strains thereof now susceptible to the combination even though said microorganisms or strains thereof were previously found or were considered resistant or intolerant to at least one of the components of the novel composition, when the at least one component was used alone at what was considered an effective dosing amount or concentration.

    摘要翻译： 至少一种形式的磷霉素（或其合适的类似物或衍生物）和至少一种磺酰胺（或其合适的类似物或衍生物）和/或至少一种二氨基吡啶（或合适的类似物或衍生物） 物）。 所述抗微生物组合物通常包括两种或多种所述组分作为新组合，以单一组合或制剂提供，或独立地提供两种或多种组分的重叠曝光。 当作为两种或多种组分提供时，这些新型组合物对抗敏感微生物是有效的，并且对抗易感药物抗性微生物（例如细菌，寄生虫）是有效的，包括多重耐药细菌。 这些新型组合物对于现在对组合敏感的微生物或其菌株也是有效的，即使先前发现了所述微生物或其菌株，或者当所述至少一种成分被认为是对所述新组合物的至少一种成分具有抗性或不耐受性时 被单独用于被认为是有效的给药量或浓度。